Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 10, 2007, Pages 1083-1087

  Van Rijn, M J E ^a   Bos, M J ^a   Isaacs, A ^a   Yazdanpanah, M ^a   Arias Vasquez A ^a   Ch Stricker, B H ^a   Klungel, O H ^b   Oostra, B A ^a   Koudstaal, P J ^a   Witteman, J C ^a   Hofman, A ^a   Breteler, M M B ^a   Van Duijn, C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BRAIN DISEASE; BRAIN INFARCTION; CAROTID ARTERY DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; WHITE MATTER; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANGIOTENSINOGEN; CAROTID ARTERY DISEASES; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; COHORT STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYPERTENSION; MALE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 34848862776     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.109819     Document Type: Article

References (34)

1. MacGregor GA, Markandu ND, Roulston JE, et al. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature 1981;291:329-31.
2. Paillard F, Chansel D, Brand E, et al. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 1999;34:423-9.
3. Schmidt H, Aulchenko YS, Schweighofer N, et al. Angiotensinogen promoter Bhaplotype associated with cerebral small vessel disease enhances basal transcriptional activity. Stroke 2004;35:2592-7.
4. Bis JC, Smith NL, Psaty BM, et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003;16:1011-17.
5. Bozec E, Fassot C, Tropeano AI, et al. Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment. Clin Sci (Lond) 2003;105:637-44.
6. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscier Thromb Vasc Biol 2003;23:1269-75.
7. Um JY, Moon KS, Lee KM, et al. Polymorphism of angiotensin-converting enzyme, angiotensinogen, and apolipoprotein E genes in Korean patients with cerebral i nfarction. J Moi Neurosci 2003;21:23-8.
8. Schmidt R, Schmidt H, Fazekas F, et al. Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities. Hypertension 2001;38:110-15.
9. Takami S, Imai Y, Katsuya T, et al. Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 2000;13:121-7.
10. Schmidt H, Fazekas F, Kostner GM, et al. Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke 2001;32:405-12.
11. KainulainenK, Perola M, Terwilliger J, et al. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension 1999;33:844-9.
12. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-9.
13. Tiret L, Bonnardeaux A, Poirier O, et al. Synergistic effects of angiotensin- converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910-13.
14. Rubattu S, Di Angelantonio E, Stanzione R, et al. Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: A role of the a1166c/at1 gene variant. J Hypertens 2004;22:2129-34.
15. Takami S, Imai Y, Katsuya T, et al. Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 2000;13:121-7.
16. Poirier O, Georges JL, Ricard S, et al. New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde. J Hypertens 1998;16:1443-7.
17. Chaves FJ, Pascual JM, Rovira E, et al. Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension. Am J Hypertens 2001;14:364-70.
18. Szolnoki Z, Melegh B. Gene-gene and gene-environment interplay represent specific susceptibility for different types of ischaemic stroke and leukoaraiosis. Curr Med Chem 2006;13:1627-34.
19. Hofman A, Grobbee DE, de Jong PT, et al. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-22.
20. Hofman A, van Laar A, Klein F, et al. Coffee and cholesterol. N Engl J Med 1983;309:1248-50.
21. van Gent CM, van der Voort HA, de Bruyn AM, et al. Cholesterol determinations. A comparative study of methods with special reference to enzymatic procedures. Clin Chim Acta 1977;75:243-51.
22. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circuiation 1997;96:1432-7.
23. Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003;34:1126-9.
24. de Leeuw FE, de Groot JC, Oudkerk M, et al. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 1999;46:827-33.
25. Tabara Y, Kohara K, Nakura J, et al. Risk factor-gene interaction in carotid atherosclerosis: effect ofgene polymorphisms ofrenin-angiotensin system. J Hum Genet 2001;46:278-84.
26. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
27. Bunnemann B, Fuxe K, Ganten D. The brain renin-angiotensin system: localization and general significance. J Cardiovasc Pharmacol 1992;19(Suppl 6):S51-62.
28. Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: The Rotterdam Scan Study. Stroke 2003;34:1126-9.
29. Hollander M, Hak AE, Koudstaal PJ, et al. Comparison between measures of atherosclerosis and risk of stroke: The Rotterdam Study. Stroke 2003;34:2367-72.
30. Steffens DC, Krishnan KR, Crump C, et al. Cerebrovascular disease and evolution of depressive symptoms in the cardiovascular health study. Stroke 2002;33:1636-44.
31. Minett TS, Dean JL, Firbank M, et al. Subjective memorycomplaints, white-matter lesions, depressive symptoms, and cognition in elderly patients. Am J Geriatr Psychiatry 2005;13:665-71.
32. Bleumink GS, Schut AF, Sturkenboom MC, et al. Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. Pharmacogenet Genomics 2005;15:75-81.
33. Baudin B. Angiotensin I-converting enzyme gene polymorphism and drug response. Clin Chem Lab Med 2000;38:853-6.
34. Hingorani AD, Jia H, Stevens PA, et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995;13:1602-9.